RENO, Nev.--(www.ipauctions.com) will auction six pharmaceutical patent applications on behalf of pharmaceutical technology company Accu-Break Pharmaceuticals, Inc. (ABP) (www.accubreak.com) of Plantation, Florida, United States.)--IpAuctions, Inc. (
“because the focus and strategy of the Company has changed with the development of its innovative Accu-Break® tablet technologies”
The first of the available applications, entitled “Method of Treating Hypertension With A Very Low Dose of Chlorthalidone,” has a number of claims already allowed. Allowance of additional pending claims appears to be available by making minor amendments, such as changing the claim dependency. NIH-sponsored studies have indicated that chlorthalidone (CTD) is safer and more effective than hydrochlorothiazide (HCTZ) and as a result, CTD became the diuretic of choice for a number of major NIH outcomes studies, including ALLHAT. CTD is approximately twice as potent as HCTZ and provides several day control of blood pressure compared to HCTZ, which is barely a once-a-day product. An opportunity to potentially provide a 6.25mg dose of CTD (especially in combination with a second antihypersensitive agent) would yield a product with an improved side-effect profile and efficacy. There are no low-dose CTD products on the market today, despite its proven safety and efficacy.
The second application is directed to “Methods of Treating Dialysis-Induced Hypotension,” and claims a novel treatment using an antihypotensive, e.g., midodrine, desglymidodrine, or the like. There is a present need for an effective treatment of intra-dialytic hypotension (IDH) that occurs in patients undergoing dialysis for acute renal failure. There is also a need for symptomatic treatment, in addition to the prophylactic use, of an antihypotensive agent to increase systolic blood pressure in a patient while undergoing dialysis. This application discloses novel methods of treating and preventing the serious and unpleasant syndrome of IDH in dialysis patients while undergoing treatment, including treatment for acute renal failure.
The third application is for "Compositions and Methods Using a Cardiac Glycoside." This application claims methods and dosage forms using a low dose of digoxin or digitoxin in patients suffering from reduced creatinine clearance, renal insufficiency or chronic renal failure, and concomitant cardiovascular disease. The application is currently under a restriction requirement for election of the methods or dosage forms as described and claimed.
The fourth application relates to "Novel Compositions and Treatment of Type II Diabetes and Hypertension" and claims methods and dosage forms using a thiazolidinedione (glitazone) in combination with a thiazide or thiazide-type diuretic (e.g., HCTZ) to prevent or treat edema induced by the glitazone. This treatment is advantageous over the recommended withdrawal of glitazone administration following development of the side effect of fluid retention, and may be an effective alternative to the use of loop diuretics.
The fifth application is for "Compositions and Methods Using Torsemide" and claims clinical utility of low-dose torsemide, and dosage forms having novel score patterns that readily provide those low doses. Also included as part of the invention are products combining torsemide with antidiabetics, such as glitazones. These novel approaches can provide the advantages of lower doses (and consequent lower side effects) while providing greater dosing flexibility during treatment, e.g., a graduated dosing regimen in pre-diabetic patients.
The sixth application relates to "Compositions and Methods Comprising a Thiazide Diuretic and a Mineralocorticoid Inhibitor." This application claims methods and dosage forms employing low doses of an aldosterone antagonist (mineralocorticoid inhibitor), such as spironolactone or eplerenone, and a thiazide, such as chlorthalidone, for co-administration or in a combination dosage form. The lower doses of active ingredient(s) allow for reduced side effects, including lower risk of potassium loss (hypokalemia), with additive or synergistic effects for treatment or prevention of cardiovascular diseases, such as hypertension, heart failure, and related disorders.
ABP is selling the patent applications "because the focus and strategy of the Company has changed with the development of its innovative Accu-Break® tablet technologies," explained Robert I. Goldfarb, President of ABP.
About Accu-Break Pharmaceuticals, Inc.
ABP is a private pharmaceutical technology company headquartered in South Florida. ABP is developing Accu-Break® technologies for pharmaceutical tablets. The innovative and patented technologies allow the creation of tablets that can be easily divided by hand into exact smaller doses, offering complete dose flexibility via risk free tablet splitting. The Company believes that these Accu-Break® technologies offer a differentiated and clinically beneficial advantages compared to conventional dosage forms and may be applied to single and combination drug products, standard and controlled release formulations with broad applicability in human and veterinary prescription and OTC medicines. Accu-Break technologies can provide:
Product differentiation through value added product enhancements
Life cycle management
Solutions for incompatible APIs
Easy dose adjustment for accurate and customized dosing needs
Clinical trial efficiencies through the use of multi-dose tablets
About IpAuctions®, Inc.
IpAuctions®, Inc. (www.IpAuctions.com) is the leading online auction firm specializing in the sale of intellectual property assets. The firm has a proprietary worldwide database of over 8,500 IP attorneys, corporate and private buyers, and venture capitalists who wish to monetize their intellectual property.